Skip to content

UPDATE: We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.

Important information regarding deferral of the Australian Register of Therapeutic Goods (ARTG) cancellation of Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate).

The Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.

The products affected are:

Di-Gesic (dextropropoxyphene HCl 32.5mg/paracetamol 325 mg) 20’s- Aust R 52509

Doloxene (dextropropoxyphene napsylate 100 mg) 10’s- Aust R 161853

This means that pharmacists may continue to dispense Di-Gesic and Doloxene until further notice.

The AAT is expected to hear the appeal within the next 4 months. If, following that appeal, a decision is made to cancel the registrations of Di-Gesic and Doloxene, these products will  then cease to be available within a short timeframe.

Further news will be available on this website as it becomes available.

Please feel free to leave any comments regarding Di-Gesic or Doloxene in the form below.  f you have any questions regarding the above information please contact us.

If you are taking Di-gesic or Doloxene and have any concerns please discuss them with your Doctor or Pharmacist. 


Content Last Reviewed On July 16, 2018

Scroll To Top